How are liver-derived inhibitors (antithrombin, protein C/S) affected in liver disease and what is the consequence?

• A. Decreased synthesis leading to risk only of bleeding
• B. Decreased synthesis leading to complex hemostatic changes; risk of both bleeding and thrombosis
• C. Increased synthesis leading to bleeding risk
• D. No change in synthesis; no effect

Answer: (B)

In liver disease, the liver’s ability to synthesize many coagulation-related proteins declines, including both procoagulant factors and natural anticoagulants like antithrombin and proteins C and S. When these inhibitors are reduced, the body's braking system on clot formation is weaker. At the same time, the amount of procoagulant factors is also lower, so there isn’t a straightforward tilt toward bleeding or toward clotting. The result is a rebalanced but fragile hemostatic system: minor insults or additional stress can tip it toward bleeding, while other factors can tip it toward thrombosis. In practice, patients with liver disease can experience bleeding due to overall coagulopathy, but they also have a notable risk of thrombosis, such as portal vein thrombosis, because the loss of anticoagulant controls is significant. This concept explains why the correct choice highlights decreased synthesis of liver-derived inhibitors with complex hemostatic changes and a dual risk of bleeding and thrombosis.